zacks.com · 3 jul

Will Briumvi's Strength Continue to Aid TGTX's Top Line in Q2?

TG Therapeutics continues to witness rising Briumvi demand. Investors are closely watching the sales numbers of the drug.

benzinga.com · 18 jun

TG Therapeutics Stock Rises Thursday: What's Driving The Gains?

TG Therapeutics Inc. (NASDAQ:TGTX) shares are trading higher on Thursday as traders keep leaning into recent upbeat clinical updates around BRIUMVI.

investors.com · 17 jun

TG Therapeutics Stock Is On A Hot Streak: Why It's Up 70% And Climbing

TG Therapeutics stock is on an absolute rampage, climbing 70% in roughly the first six months of the year, as the biotech takes on Roche.

zacks.com · 11 jun

TG Therapeutics (TGTX) Soars 7.5%: Is Further Upside Left in the Stock?

TG Therapeutics (TGTX) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock suggests that there could be more strength down the road.

zacks.com · 10 jun

TGTX Rises on Positive Phase I Data for Subcutaneous Briumvi in MG

TG Therapeutics gains after positive phase I data for subcutaneous Briumvi in myasthenia gravis or MG, while a phase II study in MG gets underway.

seekingalpha.com · 9 jun

TG Therapeutics, Inc. (TGTX) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript

TG Therapeutics, Inc. (TGTX) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript

globenewswire.com · 9 jun

TG Therapeutics Announces Positive Topline Phase 1 Data for Subcutaneous BRIUMVI in Patients with Myasthenia Gravis and Initiation of Potential Registration Directed Randomized Phase 2 Trial

82% of subjects achieved an MCID in their MG-ADL with a mean >4 point improvement in MG-ADL observed in Phase 1 study of Subcutaneous BRIUMVI in patients with MG (n=11) Potential registration-directed Phase 2 trial utilizes novel sequential treatment approach designed to combine rapid symptom control of FcRn inhibition with sustained disease modification of B-cell depletion therapy NEW YORK, June 09, 2026 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc.

globenewswire.com · 9 jun

TG Therapeutics Announces Positive Topline Phase 1 Data for Subcutaneous BRIUMVI in Patients with Myasthenia Gravis and Initiation of Potential Registration Directed Randomized Phase 2 Trial

82% of subjects achieved an MCID in their MG-ADL with a mean >4 point improvement in MG-ADL observed in Phase 1 study of Subcutaneous BRIUMVI in patients with MG (n=11)